Elutia (ELUT) said Monday it has agreed to a national group purchasing contract for its EluPro antibiotic-eluting cardiac implant with Premier (PINC), allowing Premier members to take advantage of special pre-negotiated pricing for the heart rhythm management device.
Financial terms and other details of the new contract weren't disclosed.
EluPro was developed to deliver powerful antibiotics directly to the surgical site, helping promote healing and reducing inflammation and scarring by forming a vascularized pocket of the patient's tissue surrounding the implantable device, Elutia said.
Elutia shares recently were up nearly 4% in early trading Monday, while Premier's shares were down 0.7%.
Price: 4.30, Change: +0.16, Percent Change: +3.86
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。